Loading...
•
Sep 30, 2022
Teva Q3 2022 Earnings Report
delivered a solid third quarter amidst foreign exchange headwinds
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported a decrease of 8% in revenues compared to the third quarter of 2021, with revenues of $3,595 million. GAAP diluted EPS was $0.05 and Non-GAAP diluted EPS was $0.59. The company generated $543 million in cash flow from operating activities and $685 million in free cash flow.
Revenues of $3.6 billion
GAAP diluted EPS of $0.05
Non-GAAP diluted EPS of $0.59
Free cash flow of $685 million
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva revised its 2022 revenues outlook due to continued foreign exchange headwinds, but reaffirmed its operating income, Adjusted EBITDA, EPS, and free cash flow guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income